In Porter’s first issue of Porter & Co. Biotechnology, he recommended one of the key players in gene silencing, Arrowhead Pharmaceuticals (Nasdaq: ARWR). However, he felt that we needed to wait for a better entry price. In that August 1 issue, he said that Arrowhead had done everything right: its triglyceride drug is approved and selling, it has pushed gene silencing into muscle, fat, lung, and brain, and the large drugmakers have paid Arrowhead billions for access. The stock had run from $15 to $87 in the past year. We want to own this company below $75, he concluded.

Shares of Arrowhead Pharmaceuticals are now trading around $67 per share, so we are moving them from our watchlist into a “buy” recommendation, below $75.

Action to Take: Buy Arrowhead Pharmaceuticals (Nasdaq: ARWR) below $75 per share

The post Moving Arrowhead Pharmaceuticals Off The Watchlist appeared first on Porter & Co..